Diagnostics

With demand for blood and plasma soaring, Canadian Blood Services is betting on national pride to solve a critical shortage. But can a new campaign work?

Over 120 advocates, sharing powerful personal stories, descended on Capitol Hill to demand action on the National Plan for Epilepsy Act and vital research funds.

Autoimmune diagnostics firm Exagen reports a 12% revenue jump and improved efficiency, fueling analyst optimism and setting a strong tone for 2026.

OM1's AI platform analyzed 650,000 patient records, setting a new precedent for using real-world evidence in major regulatory approvals.

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

The specialty manufacturer reports a 46% profit surge, fueled by strong demand for its key drug and a major distributor's comeback. What's next?

For the 8th straight year, Equashield dominates the CSTD market. We explore the tech, trust, and automation driving its success in protecting workers.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

Artivion posts strong Q1 results and acquires Endospan for its FDA-approved NEXUS system, yet lowers its full-year guidance. What's behind the mixed message?

With new SAFE financing, Cubit Diagnostics advances its all-in-one molecular and immunoassay platform, aiming to revolutionize point-of-care STI testing.

A leading scientific body is ditching 'longevity' for 'geroscience,' aiming to bring scientific rigor to a field rife with hype and misinformation.

With a massive new war chest, the secretive Multi Investment plans to pour capital into fintech, deep tech, and biotech, shaking up innovation funding.

The diagnostics firm's stellar quarter is fueled by surging test volumes and a new non-invasive prenatal test poised to disrupt high-risk screening.

AI/R's new 'Algorithm' and focus on Agentic AI Engineering signal a market shift from AI potential to pragmatic, results-driven business transformation.

Opening the cabin for the season? A rare but deadly virus may be waiting. Experts warn of hantavirus and share critical steps for a safe spring cleanup.

Patient ambassadors are on Capitol Hill urging lawmakers to pass bills protecting living organ donors and improving access to innovative kidney treatments.

Preclinical data for CITY-RBP4 shows promise in treating Stargardt disease, a leading cause of juvenile blindness with no approved therapies.

A Marine veteran and stand-up comedian is running for Congress in Florida. Can Tim Wilkins' outsider campaign and conservative platform win over a key district?

Empire Genomics & Molecular Instruments launch NISH, a fully automated system promising faster, clearer RNA-ISH results by preserving precious tissue samples.